CAR T Cell Therapy for Leukemia
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase Ib/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (ALL).
Are You a Good Fit for This Trial?
Adults over 18 with B cell acute lymphoblastic leukemia that's come back or hasn't responded to treatment. They must have a certain level of cancer cells in their bone marrow, be relatively healthy (ECOG status 0 or 1), and not have severe infections or other specific blood diseases. People with heart, liver, kidney, or lung problems can't join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Leukapheresis
Collection of white blood cells from participants to engineer CAR T cells
Pre-conditioning
Participants undergo pre-conditioning chemotherapy to prepare for CAR T cell infusion
Treatment
Participants receive a total target dose of 410E+6 CAR T cells as a split dose on Day 1 and Day 10
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- AUTO1
Find a Clinic Near You
Who Is Running the Clinical Trial?
Autolus Limited
Lead Sponsor